Can a simple vibratory back massage induce neo-coronary growth? a literature review and initial experience in view to pilot testing

Abstract

Background: Coronary Artery Disease (CAD) is a leading source of morbidity, and search continues for viable therapeutic options to stimulate neo-coronary growth. Low sonic Frequency Vibration (LFV) can induce fluid shear forces and cyclic stretch / strain to endothelial cells and extracellular matrix which is known to up-regulate expression of pro-angiogenic mediators such as Nitric Oxide, Vascular Endothelial Growth Factor, and other shear responsive proteins. Further, cyclic stretch of coronary microvascular cells has shown to induce coronary angiogenesis in-vitro, and LFV promoted arteriogenesis has recently been demonstrated in vivo. Interestingly there has been no work which address whether transthoracic LFV could induce neo-coronary growth in CAD patients.

Methods: To investigate feasibility we present an initial experience (n=1) in use of transthoracic LFV whereby an eighty year old male with New York Heart Classification (NYHC) Class 3 heart failure and inferior ischemia (by Persantine 99mTc Myoview scan) was provided a vibrator (27-35Hz, 6mm) for application to his upper back for 15-30 minute daily home based massage sessions planned for a three month period. Time spent and feelings regarding treatment were recorded.

Results: Home delivered device use was feasible, averaging ~3 times per week. There were no lasting adverse safety concerns – although transient musculoskeletal discomforts were reported. While effectiveness of the therapy was not a focus of this study, repeat Myoview testing following 3.5 months of therapy in this single test subject showed an absence of resting and provokable ischemia with reportedly “homogenous uptake - no defects”, and patient’s heart failure improved from Class 3 to 2.

Conclusion: We report an initial experience in use of transthoracic LFV in an IHF patient in view to promoting neo-coronary growth. In view of correlative data that shear producing and oscillative therapies reportedly induce neo-arterial growth, further pilot testing of transthoracic LFV in a statistically relevant number of CAD patients appears warranted.

Keywords: vibration, vibroacoustic therapy, upper back massage, coronary angiogenesis, arteriogenesis, refractory angina, Transthoracic, ischemic heart failure

Abbreviations: bFG, basic fibroblast growth factor; CABG, coronary artery bypass grafting; CAD, coronary artery disease; EECP, enhanced external counter pulsation; EF, ejection fraction; ERK, extracellular signal-regulated kinase; ESMR, extracorporeal ultrasonic shock wave for myocardial revascularization; IHF, ischemic heart failure; LFV, low sonic frequency vibration; NO, nitric oxide; NYHA, New York Heart Association (heart failure class system); PCI, percutaneous coronary intervention; RFA, refractory angina; SPECT, single photon emission computed tomography; VEGF, vascular endothelial growth factor

Introduction

Management of advanced Coronary Artery Disease (CAD) is a difficult challenge. Refractory Angina (RFA) for example is a debilitating disease characterized by severe, easily provokable cardiac pain resistant to all conventional treatments for CAD. These individuals suffer severely impaired health-related quality of life with recurrent and sustained pain and/or breathlessness, poor general health status, psychological distress and activity restrictions. The global prevalence of RFA is increasing, with available estimates suggesting that RFA affects between 600,000 and 1.8 million people in the United States1,2 with as many as 50,000 new cases each year, and 30,000-50,000 new cases per year in continental Europe3,4. The European Society of Cardiology concurs that 15% of patients who experience angina can be characterized as having RFA and that as the population ages and CAD mortality decreases, the number of patients with the condition is likely to increase.1 Surgical and interventional options for RFA patients have usually been exhausted or have resulted in only partial revascularization, so therapy is limited to multiple anti-anginal medications, reduced activity and support group therapy.
Ischemic Heart Failure (IHF) is another debilitating disease, often co-morbid with RFA, and in itself carrying a high prevalence in society.4 The burgeoning field of stimulation of neo-coronary growth (whether by angiogenesis-growth of new coronary arterioles and capillaries, or arteriogenesis - growth of pre-existing collaterals) offers hope for these patients.3 The goal of this approach is to induce growth of new or pre-existing vasculature to perfuse ischemic myocardial territories otherwise unapproachable by angioplasty and bypass surgery. The delivery of angiogenic growth factors has been a major research focus over the last decades, but unfortunately despite encouraging preclinical data have so far shown only at best bare minimal improvements in myocardial perfusion, cardiac function, and clinical outcome.19

A variety of non-invasive mechanical techniques for inducing neo-coronary growth have been gaining attention as it has been solidly established that introduction of shear stresses and cyclic stretch or strain to endothelial cells (and/or the extracellular matrix between the cells) can lead to the endogenous liberation of multiple beneficial pro-angiogenic factors16,20 and growth of new arterioles and capillaries.21,22 Enhanced External Counter Pulsation (ECCP) for example, involving forceful diastolic timed leg compressions (which send retrograde pulses of blood to augment fluid shear stresses to coronary endothelial cells) has shown to increase treadmill time to ST depression and diminish anginal counts (although without change in NTG usage) in the randomized control MUST-ECCP trial23 although the authors admit the difficulty in blinding patient’s from sham therapy hence placebo effect (a strong factor in evaluation of anti-anginal therapies)18 remains a lingering question. ECCP however is also uncomfortable and can be injury producing to the patient1, and has shown a suboptimal inverse correlation in effectiveness related to the extent of coronary artery disease - possibly because of the requirement of a proximal patent conduit to transmit the augmented pressure pulse to a diseased vasculature.32,33

Extracorporeal ultrasonic Shock wave delivery for Myocardial Revascularization (ESMR- Cardiospec, Medispec Ltd) has recently emerged as a safer, less painful non-invasive technique which delivers ultrasonic imaging guided shock waves to a targeted ischemic myocardium which purportedly induce liberation of angiogenic related growth factors.34 However a highly skilled professional for targeting the shock waves is needed (hence the technique may not be available or affordable to all patients) and ESMR’s therapeutic impact is somewhat questionable with a noted absence of randomized controlled clinical trials (again placebo effect?) and RFA studies showing only borderline to absent improvements of empirically measurable improved perfusion.35,36

Hence a safe, inexpensive, practical, non-invasive therapy for treatment of chronic myocardial ischemia is required, preferably one which does not rely upon patent proximal vessels nor advanced imaging techniques, and preferably deliverable by self-administration in the comfort of one’s home. In view of very recent industry reports that non-invasively applied Low sonic Frequency Vibration (LFV) can promote arteriogenesis in vivo,37 and given in-vitro data that periodic cyclic stretch of coronary endothelial cells and cardiac myocytes promote coronary angiogenesis,21-23 we have taken a first step in addressing the question whether transthoracic LFV may grow new coronary vessels in the ischemic heart. To that end we provide a feasibility case study involving LFV massage to the upper back in an elderly male with documented IHF as a self-administered home based therapy. Experience gained by this study should assist in device selection and protocol development for future pilot work in this field.

Materials and methods

This study was performed by Ah of Biophysical Systems Inc. (Burnaby, BC, Canada), following institutional approval consistent with the ethical standards on human experimentation per the Helsinki Declaration of 1964 and its later amendments. Informed consent was obtained from a single Volunteer (n=1); an 80 year old retired male living in an assisted living facility with documented inferior wall myocardial ischemia - apex to base - both at rest, and with further extension of the perfusion defect with stress (according to Persantine 99mTc Myoview nuclear scan). Additional informed consent was also obtained regarding use of the Volunteer’s photograph and medical images as was required in publishing this article.

We hypothesize that upper torso LFV therapy administered for 15-30 minutes daily treatment sessions over a three to four month period may lead to a correction of myocardial ischemic zones and improvement of heart failure status, perhaps by a mechanism of neo-coronary arterial growth. The aim of this study was to gain an initial experience (i.e. to assess feasibility and insights towards safety) regarding use of this technique. We hope information gleaned by this study may offer insights towards device development and later pilot study planning with a statistically relevant number of participants.

Volunteer’s demographics and medical findings preceding LFV therapy

Age: 80 years
Gender: Male
Weight: 200 lbs
Height: 67 inches
Non smoker

Resting EF: 41% (By Persantine Myocardial Perfusion Scan), with “Global hypokinesis, most conspicuously at the inferior wall”.
Heart Rhythm: Chronic AF, with VVI pacemaker.
Functional Limitation: NYHC 3, marked SOB requiring rest after slowly walking 3 minutes on a flat (no incline). Unsteady on feet, (poor balance) even for short distances.
Exercise routine: Independent daily dressing, walking to bathroom and for meals, walks dog short distance outside once a day with multiple rest breaks.

Medication List

Flomax CR 0.4mg-1 tablet per day
Fluoroside 40mg-1 tablet AM, and at lunch
Quinine Sulphate 200 MG,-1 capsule at bedtime
Warfarin 2mg.-1 tablet in the evening
Simvastatin 20mg-1 tablet in the evening
Bisoprolol 10 mg-1 capsule daily  
Ramipril 5mg-1 capsule in the morning  
Venlafaxine XR 75mg-1 capsule at bedtime  
Ranitidine 150mg-1 tablet morning and evening  
Dettol 2mg-½ tab, twice a day  
Venlafaxine 37.5mg-1 capsule at bedtime

We chose a commercially available percussive vibrator which had an output of 6 mm displacements applicable at a range of selectable impact frequency settings (level 1-20Hz, level 2-24Hz, level 3-27Hz; level 4-31Hz and level 5-35Hz).

The Volunteer was instructed to place the vibrator behind his upper back and recline against it while sitting in a chair with the contact nodes of the device disposed to the left and right of the spine predominantly between the shoulder blades. The Volunteer was further instructed to use the highest frequency/intensity level tolerable (to a level of comfort) daily, for 15-30 minute sessions for a period of at least 3 months and up to when a repeat Myoview scan could be arranged. It was recommended to apply LFV while watching television, and that a session should be immediately terminated (with the investigator contacted) should the Volunteer feel light headed, weak, shortness of breath, chest pain or undue back pain during or immediately after a therapy session. The Volunteer had reportedly never utilized a vibration massager for routine use on his back previously. Figure 1 showing the Volunteer relaxing watching TV with device applied.

Results

On introductory use (during a home visit), effective penetration from our Volunteer’s upper back to thoracic cavity was confirmed by what we have termed the “ahhhhh test”\(^2\), whereby the subject with device applied uttered the phrase “ahhhhh”, whereby vibratory undulation in the subject’s voice confirmed effective transthoracic penetration. The volunteer was instructed to always check for a positive “ahhhhh test” at the beginning and periodically during each daily therapy session to optimize device positioning. An investigator paid bi-weekly home visits to the Volunteer, to ensure maintenance of the device and that the subject had no significant adverse events.

\(^2\)To view the Volunteer undergoing the “ahhhhh” test, a video can be accessed on the Internet at the following address: https://www.youtube.com/watch?v=5u3s1yr1x9o

Figure 1 The Volunteer watching TV while reclining against the vibrator. To view this scene in action a video is available on the internet at https://www.youtube.com/watch?v=qj43Kf_z3oY.

With the device used at higher intensity levels further comments of “back sore” were again noted whereby the Volunteer missed a pair of following daily sessions. The Volunteer indicated that he was not at all certain however that the device caused his back to feel sore as he often experienced similar symptoms “naturally” (regardless of use of the device), which he felt was brought on typically by “nervous anxiety” or “tension”. It was also noted by diary record that the Volunteer did not always use the device the day before his reported back symptoms, and on one occasion he even indicated that the device “seems to be helping my back”.

Of particular concern midway through the course of therapy our Volunteer recorded “My heart has began to be sore, the machine may be too strong”. On bi-weekly visit the Volunteer was counseled that he should have called the Investigator on this occasion and sought hospital attention by dialing 911. The Volunteer indicated however that he was actually uncertain at the time whether the discomfort was originating from his heart or upper back, and that the discomfort was only briefly noted immediately following use of the device, and seemed to have a postural component (“got better in certain positions and with stretching”). Our Volunteer indicated however that he was generally worried about using the device until he received reassurance from his physicians, (including his General Practitioner and Cardiologist), and that he had therefore temporarily stopped using the device. This was of course agreed upon by the Investigators, and the Volunteer reported he had received re-assurance from his physicians that it was safe to use the device (which is a regulatory class 1, therapeutic massager) at his discretion preferably at low to medium levels to start where-after vibration therapy commenced.

Other device use reportings included “head ache”, “neck sore”, “sore stomach”, “private parts sore”, “bones sore”, however upon interview it appeared that he was experimenting with the device and placing it at times to his lower back and hip region, whereby after therapy he noticed soreness to “stomach” and “private parts”. After experiencing these sensations the volunteer reportedly kept use of the device to the mid and upper back, and stated that there were no subsequent like adverse occurrences to at least the lower torso region.

Typical use was at home, reclining against the vibrator, while watching TV. Our volunteer used three differing vibro-percussion frequencies / intensity levels depending how he felt for the day, all being at 6 mm amplitude: a) (27Hz, low intensity), b) (31Hz – moderate intensity) and c) (35Hz – highest intensity). The subject did not reportedly alter his medications or his general his life style (including exercise regimen) over the course of the study. A log of the patient’s use of the device has been transcribed from original data, provided in Table 1.

Following 109 days of prescribed upper back LFV therapy, repeat Persantine 99mTc Myoview scan SPECT images were acquired and interpreted by a third party qualified Nuclear Medicine physician (Surrey Memorial Hospital, B.C. Canada) as normal with “no evidence of ischemia or infarction” and with the attenuation corrected perfusion images demonstrating “homogeneous uptake and no defects” (Figure 2, showing pre and post stress VLA Spect images). Moreover, we took the patient for a normal paced walk (100 meters, no incline), without evidence of undue dyspnea or fatigue. Our volunteer’s resting ejection fraction remained substantially unchanged from baseline, at 40%.

![Figure 2](image-url)  Note enhanced perfusion particularly in the inferior-posterior wall extending to the apex.

**Discussion**

A feasibility case study is reported where a simple, semi-regular home use of a low frequency vibrator used in the ~27-35Hz range was intermittently employed over a three and a half month period in treatment of an eighty year old male with known CAD (evidenced by inferior wall ischemia extending from apex to base, by Persantine 99mTc Myoview nuclear scan) and NYHC class 3 heart failure. To the Author’s knowledge this is the first reported experience relating to an LFV application (in this case applied locally to the upper back) in an IHF patient.

It should be stressed that this study’s purpose was only to explore an initial experience relating to LFV as a home based therapy in a CAD patient with a moderately reduced ejection fraction, and should be viewed only as a first step in pursuit of device selection / development and pilot testing in treatment of RFA and / or IHF.

It is well accepted that increased levels of fluid shear stress and cyclic stretch / strain (or deformation) of vascular endothelial cells and / or extracellular matrix triggers activation of neo-arterial growth, 21-28 and this is importantly true with cardiac myocytes and coronary microvascular endothelial cells. 21,23 As LFV is characterized by rapidly changing compressive and expansive forces in tissue it is reasonable to postulate that the fluid and endothelial cells within the vasculature would be exposed to such pro-angiogenic stimuli. Indeed, hydrodynamic analysis indicates that shear stress at the wall of vessels (including the coronaries) is significantly increased during bodily exposure to LFV in the low sonic ranges, 28 hence the triggering of neo-arterial growth by vibration can therefore be hypothesized.

That LFV in particular may yield neo-arterial growth has been supported by Zou and his associates who found that locally applied transcranial vibration at 250 Hz demonstrated an increased expression of VEGF (a key player in extravasations of plasma proteins, endothelial cell proliferation and migration), as well as VEGF-R2, TNF-alpha, TNF R1 and R2 in the Guinea Pig coelchea. 29 LFV is also known to trigger Nitric Oxide (NO) release 40-42 which particularly along with ischemia is a well known pro-angiogenic mediator in up-regulation of VEGF transcription. 43 LFV has also shown to be a potent vasodilator particular in arteries with pre-existing spasm or heighted vascular tone, 44,45 whereby this may hold additional relevance in that changing vascular wall tension has been suggested to lead to release of proteases initiating endothelial cell proliferation. 25 Moreover mechanical perturbations such as stretching of endothelial cells or extracellular matrix (basement membrane) has been shown to release stored bFGF-an angiogenic cytokine responsible for endothelial and smooth muscle cell proliferation. 46,48 Also, the intensive growth of endothelial cells exposed to pulsed electromagnetic fields in vitro (which leads to a mechanical oscillatory response to the cells) 10 further foreshadows a potential mitogenic effect by oscillatory stress.

Importantly LFV at 30Hz (within the range of frequencies used in our study) has been shown to significantly increase activation of ERK1/2 (a shear responsive protein involved in cell proliferation) and up-regulate expression of Endothelin-1, a potent mitogen and proliferator for endothelial cells. 50,51 Further, liberalization of circulating levels of VEGF have also been shown by Suhr et al. 52 in their studies of cyclists upon a vibrating platform (30Hz, 4mm). 52 Moreover recent advances in LFV wound healing by promotion of arteriogenesis have just recently been unveiled by use of Vibrant Medical’s VibroPulse® cycloidal vibration mat- at frequencies of less than 75Hz. 53

It should be addressed that from a safety perspective a preferred LFV system in IHF applications should be programmable to periodically cease emissions during the early to mid force generation phase of left ventricular systole, as systolic timed LFV has been suggested to cause a negative inotropic effect (i.e. a decreased strength of heart contractions) in the ischemic heart. 53 Paradoxically however, diastolic timed LFV has advantageously shown to augment ischemic left ventricular performance in animals and human volunteers, purportedly by improved left ventricular diastolic relaxation with augmented stroke volume by the Frank Starling mechanism. 54,57

We therefore suggest in future studies that patient’s with diminished ejection fractions of less than 35% receiving indiscriminately
Can a simple vibratory back massage induce neo-coronary growth? a literature review and initial experience in view to pilot testing

Penetrability of LFV from upper back to the heart was confirmed in our study by a method we refer to as the “ahhhhh” test, whereby it is inferred that robust undulations in vocal tone during upper back percussion demonstrates adequate vibratory transmission. While this technique only yields an inference that the heart and coronary vasculature are being vibrated (as the trachea and vocal cords are located in close proximity, and just anterior to the heart), effective transthoracic LFV transmission (as measured by transesophageal accelerometer and LV catheter) has been verified by Koiwa et al.44-46 in human volunteers by use of substantially lower stroke amplitude (i.e. 2mm)44-46 than what we used in our study. We should also emphasize that given our relatively large impact stroke length (6mm), that our Volunteer did complain of musculoskeletal soreness likely related to the strength of the device. For this reason a slightly less intense vibratory instrument (although which still passes the “ahhhhh” test) is suggested for future studies4.

We chose the upper back rather than chest wall for LFV applications since the Volunteer’s ischemia was inferior / posterior (rather than anterior), and it was felt that application to the back (essentially equivalent to a “back massage”) would be more comfortable, safer, and easier to self-apply. However for treatment of anterior ischemia

Conclusion

A case study is presented demonstrating feasibility of a self administered home based upper back LFV therapy over a three and a half month period in an elderly NYHA Class 3 IHF patient (n=1) with known inferior wall ischemia based on Persantine Myoview scan. Patient’s compliance in use of the device was about 50% and
no adverse safety concerns (other than transient musculoskeletal discomforts) were documented. In view of correlative mechanistic data that shear stress producing and oscillative therapies purportedly induce neo-arterial growth, continued pilot testing of this technique in a statistically relevant number of IHF and RFA patients appears warranted. We recommend study of Parallel Biotechnologies’ Yes-Reflow” Vibroacoustic Therapy system, as it can be applied to either the chest wall or upper back, enables programmable waveforms including selective diastolic timed emissions, and provides a substantially less intense (but still penetrative) massaging action.

Acknowledgements

We thank Stanley Kita for his contribution of performing a literature search regarding the field of employing mechanical stimuli to vascular tissue as a means for promoting angiogenesis, many of the publications of which we have recently reviewed and cited in the writing of this paper. We also thank Arianna Hoffmann for her assistance in photography.

Disclosure

This study was sponsored by a grant awarded by ABS Inc., an entity holding financial shares in a patent relating to use of transthoracic vibration massage for stimulating coronary angiogenesis. The Author (AH) is a director and has shares in ABS Inc. Otherwise no conflicts of interest are declared. The Author (HG) has received grants from ABS Inc. for this and other projects. The Author (AU) is CEO and director of Parallel Biotechnologies LLC, developer of the Yes Reflow Vibro-Acoustic Therapy System. Otherwise no conflicts of interest are declared.

Disclaimer

The Authors cannot warrant the safety of transthoracic LFV in humans with CAD, however vibration massagers similar to what was used in our case study are generally commercially available and regulatory certified tools for therapeutic back massage, and massage to the chest wall (such as for mobilizing pulmonary secretions in CF patients). Further the author cannot warrant the effectiveness that LFV to the thoracic cavity would indeed induce coronary angiogenesis or arterio genesis as there as of yet has been no statistically relevant clinical trials to prove such effectiveness.

Conflict of interest

The author declares no conflict of interest.

References

10. Seller C. Angiogenic therapy; is it still viable? Heart Metab. 2013;58:20–24.

Can a simple vibratory back massage induce neo-coronary growth? a literature review and initial experience in view to pilot testing